Anti-BRDT monoclonal antibody

Pre-made anti-BRDT monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to BRDT/BRDT products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T90985-Ab-1/ GM-Tg-hg-T90985-Ab-2Anti-Human BRDT monoclonal antibodyHuman
GM-Tg-rg-T90985-Ab-1/ GM-Tg-rg-T90985-Ab-2Anti-Rat BRDT monoclonal antibodyRat
GM-Tg-mg-T90985-Ab-1/ GM-Tg-mg-T90985-Ab-2Anti-Mouse BRDT monoclonal antibodyMouse
GM-Tg-cynog-T90985-Ab-1/ GM-Tg-cynog-T90985-Ab-2Anti-Cynomolgus/ Rhesus macaque BRDT monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T90985-Ab-1/ GM-Tg-felg-T90985-Ab-2Anti-Feline BRDT monoclonal antibodyFeline
GM-Tg-cang-T90985-Ab-1/ GM-Tg-cang-T90985-Ab-2Anti-Canine BRDT monoclonal antibodyCanine
GM-Tg-bovg-T90985-Ab-1/ GM-Tg-bovg-T90985-Ab-2Anti-Bovine BRDT monoclonal antibodyBovine
GM-Tg-equg-T90985-Ab-1/ GM-Tg-equg-T90985-Ab-2Anti-Equine BRDT monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T90985-Ab-1/ GM-Tg-hg-T90985-Ab-2; GM-Tg-rg-T90985-Ab-1/ GM-Tg-rg-T90985-Ab-2;
GM-Tg-mg-T90985-Ab-1/ GM-Tg-mg-T90985-Ab-2; GM-Tg-cynog-T90985-Ab-1/ GM-Tg-cynog-T90985-Ab-2;
GM-Tg-felg-T90985-Ab-1/ GM-Tg-felg-T90985-Ab-2; GM-Tg-cang-T90985-Ab-1/ GM-Tg-cang-T90985-Ab-2;
GM-Tg-bovg-T90985-Ab-1/ GM-Tg-bovg-T90985-Ab-2; GM-Tg-equg-T90985-Ab-1/ GM-Tg-equg-T90985-Ab-2
Products NameAnti-BRDT monoclonal antibody
Formatmab
Target NameBRDT
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-BRDT monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T90985-Ag-1Recombinant multi-species BRDT/ BRD6/ CT9 protein


    Target information

    Target IDGM-T90985
    Target NameBRDT
    Gene ID676,114642,305123,711998,479954,101096661,523971,100051647
    Gene Symbol and Synonyms7420412D09Rik,BRD6,BRDT,CT9,Fsrg3,SPGF21
    Uniprot AccessionQ58F21,D4A7T3
    Uniprot Entry NameBRDT_HUMAN,BRDT_RAT
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000137948
    Target ClassificationEpigenetic

    The target: BRDT, gene name: BRDT, also named as BRD6, CT9, SPGF21. BRDT is similar to the RING3 protein family. It possesses 2 bromodomain motifs and a PEST sequence (a cluster of proline, glutamic acid, serine, and threonine residues), characteristic of proteins that undergo rapid intracellular degradation. The bromodomain is found in proteins that regulate transcription. Several transcript variants encoding multiple isoforms have been found for this gene. [provided by RefSeq, Jun 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.